Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2022 | Orthopedic adverse events among AYA patients with ALL treated with asparaginase

Marlise Luskin • 28 Sep 2022

SOHO 2022

Acute Lymphoblastic Leukemia Leukemia Asparaginase Dexamethasone

In this video, Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses toxicities observed in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) treated with asparaginase, drawing focus on orthopedic adverse events, and further highlights the importance of investigating these. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Venetoclax & dose-reduced chemotherapy for the treatment of older adults with B-ALL and T-ALL

Marlise Luskin • 10 Dec 2023

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trial

Marlise Luskin • 10 Dec 2023

Asciminib plus dasatinib for the treatment of Ph+ B-ALL: insights from a Phase I trial

Marlise Luskin • 10 Dec 2023

Long-term overall survival of AYA patients with ALL who complete therapy on DFCI Consortium trials

Marlise Luskin • 11 Dec 2022

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024